© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
OAB and Incontinence
Preoperative bladder symptom score best predictor of transvaginal mesh surgery success
September 16, 2020
“Although IPSS may not be familiar to gynecologists and urogynecologists, this minimally invasive self-reported questionnaire is useful in counseling preoperative pelvic organ prolapse patients with OAB symptoms," researchers write.
Three-week test phase improves odds of success for sacral neuromodulation
September 16, 2020
“The present study clearly shows that test duration and reprogramming during the test phase increases the number of patients that benefit in the long term from sacral neuromodulation,” researchers wrote.
Telemedicine is viable option for most early midurethral sling postoperative visits
September 15, 2020
Outcomes for patients using telemedicine were equal, and patients were as satisfied as those who had office-based postoperative visits.
Smoking associated with increased incidence of OAB
September 08, 2020
Smoking had a particularly strong impact on OAB risk in younger individuals.
Overactive bladder: Another agent attempts a step forward
September 03, 2020
Gopal H. Badlani, MD, discusses the recently presented long-term safety profile of the β-3 adrenoceptor agonist vibegron.
Nocturia: How to define it, and how to treat it
August 25, 2020
Jeffrey P. Weiss, MD, PhD, discusses how he defines nocturia, how to separate the symptom from overactive bladder, and how he conducts patient work-ups for nocturia
FDA approval sought for peripheral neurostimulator for overactive bladder
August 24, 2020
Data from a pivotal trial showed the eCoin Peripheral Neurostimulator led to a clinically significant improvement in urgency urinary incontinence.
Overactive bladder treatment maintains favorable long-term safety profile
August 21, 2020
Beta 3-adrenergic receptor agonist’s benefits observed at 52 weeks, investigators report.
Pivotal study launches exploring novel device for women with OAB
August 11, 2020
The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.
FDA approves new devices for bladder and bowel control conditions
August 06, 2020
InterStim Micro treats patients with overactive bladder, fecal incontinence, and non-obstructive urinary retention by delivering sacral neuromodulation therapy.